Notícias e Atividades da Hepion Pharmaceuticals

Hepion Pharmaceuticals é uma empresa listada sob o símbolo HEPA (US).

Fusão, aquisição e financiamento envolvendo Hepion Pharmaceuticals.

• Hepion Pharmaceuticals and Pharma Two B have announced they will merge  (publicado em 8 de agosto de 2024)..

Veja o organograma con seus 5 executivos principais

Biografias mais buscadas da Hepion Pharmaceuticals

• Timothy Block, Director
• Kaouthar Lbiati, Director
• John Brancaccio, Chairman of the Board

Recentes movimentos de executivos em Hepion Pharmaceuticals

• John Cavan, Chief Financial Officer and Interim Chief Executive Officer, deixou a Companhia  (Notícia publicada em 8 de agosto de 2024).

Criar um alerta
para seguir os movimentos de executivos da Hepion Pharmaceuticals.

Hepion Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Hepion Pharmaceuticals

• Hepion Pharmaceuticals Announces Reverse Stock Split – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces $9.0 Million Public Offering – Hepion Pharmaceuticals
• Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. – Hepion Pharmaceuticals
• Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
• View more press releases Close

Redes sociais sobre Hepion Pharmaceuticals

• Hepion Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Hepion Pharmaceuticals na LinkedIn, Twitter e YouTube